{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:19:10Z","timestamp":1794071950082,"version":"4.8.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007802","name":"Italian Foundation for Amyotrofic Lateral Sclerosis Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007801","name":"Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MCNT2-2023-12377968"],"award-info":[{"award-number":["PNRR-MCNT2-2023-12377968"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["H53C24000210006"],"award-info":[{"award-number":["H53C24000210006"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.athplu.2026.100576","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:29:28Z","timestamp":1782314968000},"page":"100576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cholesterol in amyotrophic lateral sclerosis: a bystander, a biomarker, or a target?"],"prefix":"10.1016","volume":"65","author":[{"given":"Matteo","family":"Far\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Susanna","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Tremolizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-9857","authenticated-orcid":false,"given":"Chiara","family":"Pavanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2026.100576_bib1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/WCO.0000000000001411","article-title":"Neurochemical biomarkers of amyotrophic lateral sclerosis: recent developments","volume":"38","author":"Verde","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41598-021-81599-5","article-title":"Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis","volume":"11","author":"Conti","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2026.100576_bib3","article-title":"Alzheimer's association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.athplu.2026.100576_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100027","article-title":"Core blood biomarkers of Alzheimer's disease: a single-center real-world performance study","volume":"12","author":"Pozzi","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.athplu.2026.100576_bib5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(25)00262-4","article-title":"Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bensimon","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2026.100576_bib6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2026.100576_bib7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.chemphyslip.2016.05.003","article-title":"The role of cholesterol in membrane fusion","volume":"199","author":"Yang","year":"2016","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.athplu.2026.100576_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","article-title":"Cholesterol metabolism and homeostasis in the brain","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"10.1016\/j.athplu.2026.100576_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/gb-2004-5-11-248","article-title":"The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases","volume":"5","author":"Friesen","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.athplu.2026.100576_bib10","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1007\/s12035-024-04672-w","article-title":"Cholesterol metabolism in CNS diseases: the potential of SREBP2 and LXR as therapeutic targets","volume":"62","author":"Wang","year":"2025","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.athplu.2026.100576_bib11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.RES.0000143422.83209.be","article-title":"Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home?","volume":"95","author":"Ory","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.athplu.2026.100576_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0404.2006.00684.x","article-title":"Oxysterols and Alzheimer's disease","volume":"185","author":"Bjorkhem","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.athplu.2026.100576_bib13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1161\/01.ATV.0000148704.72481.28","article-title":"24(S),25-epoxycholesterol--a potential friend","volume":"24","author":"Bjorkhem","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2026.100576_bib14","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/eurheartj\/ehaf207","article-title":"ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease","volume":"46","author":"Morze","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.100576_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-19-1592-5_1","article-title":"HDL structure","volume":"1377","author":"Deng","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.athplu.2026.100576_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/HCO.0b013e3281a8acad","article-title":"Genetic determinants of HDL: monogenic disorders and contributions to variation","volume":"22","author":"Klos","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.athplu.2026.100576_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.athplu.2025.02.001","article-title":"HDL-replacement therapy: from traditional to emerging clinical applications","volume":"59","author":"Sirtori","year":"2025","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.athplu.2026.100576_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/cvr\/cvu150","article-title":"HDL in innate and adaptive immunity","volume":"103","author":"Catapano","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.athplu.2026.100576_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051041","article-title":"The endothelium is both a target and a barrier of HDL's protective functions","volume":"10","author":"Robert","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.athplu.2026.100576_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013531","article-title":"Role of high-density lipoproteins in cholesterol homeostasis and glycemic control","volume":"9","author":"Manandhar","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athplu.2026.100576_bib21","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.258644","article-title":"HDLs extract lipophilic drugs from cells","volume":"135","author":"Zheng","year":"2022","journal-title":"J Cell Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/biom10040598","article-title":"High-Density lipoproteins are bug scavengers","volume":"10","author":"Meilhac","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.athplu.2026.100576_bib23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1471-4159.2004.02373.x","article-title":"Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model","volume":"89","author":"Balazs","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.athplu.2026.100576_bib24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100576_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11883-022-00995-y","article-title":"Transintestinal cholesterol excretion in health and disease","volume":"24","author":"Garcon","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.athplu.2026.100576_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1197502","article-title":"Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy","volume":"13","author":"Tu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.athplu.2026.100576_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fncel.2014.00422","article-title":"HMG-CoA reductase inhibition promotes neurological recovery, peri-lesional tissue remodeling, and contralesional pyramidal tract plasticity after focal cerebral ischemia","volume":"8","author":"Kilic","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.athplu.2026.100576_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab143","article-title":"Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression","volume":"3","author":"Sol","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.athplu.2026.100576_bib29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0271678X231153281","article-title":"Blood-CNS barrier dysfunction in amyotrophic lateral sclerosis: proposed mechanisms and clinical implications","volume":"43","author":"Steinruecke","year":"2023","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.athplu.2026.100576_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92112-3","article-title":"Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders","volume":"11","author":"Area-Gomez","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2026.100576_bib31","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.1523\/JNEUROSCI.1388-20.2020","article-title":"Neutral lipid cacostasis contributes to disease pathogenesis in amyotrophic lateral sclerosis","volume":"40","author":"Dodge","year":"2020","journal-title":"J Neurosci"},{"key":"10.1016\/j.athplu.2026.100576_bib34","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00415-014-7445-1","article-title":"Prior medical conditions and the risk of amyotrophic lateral sclerosis","volume":"261","author":"Seelen","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib36","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/ana.24936","article-title":"Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort","volume":"81","author":"Mariosa","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib39","doi-asserted-by":"crossref","first-page":"202 e1","DOI":"10.1016\/j.neurobiolaging.2018.03.022","article-title":"Polygenic link between blood lipids and amyotrophic lateral sclerosis","volume":"67","author":"Chen","year":"2018","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.athplu.2026.100576_bib40","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.25431","article-title":"Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis","volume":"85","author":"Bandres-Ciga","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/21678421.2020.1822411","article-title":"Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis","volume":"22","author":"Bjornevik","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.athplu.2026.100576_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj0264","article-title":"Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS","volume":"14","author":"Hop","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.athplu.2026.100576_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/jnnp-2021-327133","article-title":"Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis","volume":"93","author":"Thompson","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.athplu.2026.100576_bib44","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1007\/s00415-023-11630-4","article-title":"Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry","volume":"270","author":"Michels","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/21678421.2023.2295455","article-title":"Premorbid lipid levels and long-term risk of ALS-a population-based cohort study","volume":"25","author":"Vaage","year":"2024","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.athplu.2026.100576_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48059-7","article-title":"Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis","volume":"9","author":"Chaves-Filho","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2026.100576_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41598-020-80378-y","article-title":"Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis","volume":"11","author":"Dodge","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2026.100576_bib37","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1007\/s10072-025-08407-0","article-title":"Two-step Mendelian randomization reveals a lipid-driven protective effect of type 2 diabetes on ALS","volume":"46","author":"Kong","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib38","article-title":"Amyotrophic lateral sclerosis: a diet review","volume":"10","author":"D'Antona","year":"2021","journal-title":"Foods"},{"key":"10.1016\/j.athplu.2026.100576_bib45","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awad306","article-title":"Gut microbiome correlates with plasma lipids in amyotrophic lateral sclerosis","volume":"147","author":"Guo","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.athplu.2026.100576_bib46","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host","volume":"45","author":"Khovidhunkit","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2026.100576_bib47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00415-010-5805-z","article-title":"Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis","volume":"258","author":"Dorst","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib48","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","article-title":"Dyslipidemia is a protective factor in amyotrophic lateral sclerosis","volume":"70","author":"Dupuis","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.athplu.2026.100576_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113619","article-title":"Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor","volume":"9","author":"Wuolikainen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.athplu.2026.100576_bib50","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2169\/internalmedicine.51.7465","article-title":"Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study","volume":"51","author":"Ikeda","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.athplu.2026.100576_bib51","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3233\/JAD-170660","article-title":"Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition","volume":"61","author":"Ahmed","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.athplu.2026.100576_bib52","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1212\/WNL.0b013e3181c1df1e","article-title":"Lower serum lipid levels are related to respiratory impairment in patients with ALS","volume":"73","author":"Chio","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.athplu.2026.100576_bib53","doi-asserted-by":"crossref","first-page":"e1835","DOI":"10.1212\/WNL.0000000000009322","article-title":"Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis","volume":"94","author":"Ingre","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.athplu.2026.100576_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5678698","article-title":"Association of copper status with lipid profile and functional status in patients with amyotrophic lateral sclerosis","volume":"2018","author":"Barros","year":"2018","journal-title":"J Nutr Metab"},{"key":"10.1016\/j.athplu.2026.100576_bib55","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/jamaneurol.2014.1129","article-title":"Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study","volume":"71","author":"Chio","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/21678421.2015.1062517","article-title":"Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial","volume":"16","author":"Rafiq","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.athplu.2026.100576_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.22114","article-title":"Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis","volume":"44","author":"Paganoni","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.athplu.2026.100576_bib58","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s10072-017-3138-8","article-title":"Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis","volume":"38","author":"Mandrioli","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib59","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1212\/WNL.0000000000201657","article-title":"Association between serum lipids and survival in patients with amyotrophic lateral sclerosis: a meta-analysis and population-based Study","volume":"100","author":"Janse van Mantgem","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.athplu.2026.100576_bib60","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41598-022-05714-w","article-title":"Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: roles of sex and hypermetabolism","volume":"12","author":"Nakamura","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2026.100576_bib61","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/21678421.2016.1208247","article-title":"Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: a population based study","volume":"17","author":"Kioumourtzoglou","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.athplu.2026.100576_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000526982","article-title":"Cardiovascular diseases, medications, and ALS: a population-based case-control study","volume":"56","author":"Abdel","year":"2022","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.athplu.2026.100576_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70095","article-title":"Statin use and amyotrophic lateral sclerosis survival: a population-based cohort study","volume":"32","author":"Vaage","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib64","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2026.100576_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2006.10.001","article-title":"Statin-associated adverse effects beyond muscle and liver toxicity","volume":"195","author":"Kiortsis","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.100576_bib66","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of statin therapy","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.athplu.2026.100576_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11051359","article-title":"Mendelian randomization analysis reveals statins potentially increase amyotrophic lateral sclerosis risk independent of peripheral cholesterol-lowering effects","volume":"11","author":"Wang","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.athplu.2026.100576_bib68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/21678421.2023.2255622","article-title":"Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study","volume":"25","author":"Li","year":"2024","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.athplu.2026.100576_bib69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-510X(01)00529-9","article-title":"Use of statins in CNS disorders","volume":"187","author":"Cucchiara","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib70","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1471-4159.2004.02980.x","article-title":"Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones","volume":"92","author":"Bosel","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.athplu.2026.100576_bib71","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00018-003-3018-7","article-title":"Cholesterol homeostasis and function in neurons of the central nervous system","volume":"60","author":"Pfrieger","year":"2003","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib72","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s13760-021-01753-8","article-title":"Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"122","author":"Nabizadeh","year":"2022","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.athplu.2026.100576_bib73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12916-022-02442-w","article-title":"Medication use and risk of amyotrophic lateral sclerosis-a systematic review","volume":"20","author":"Cui","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.athplu.2026.100576_bib74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00002018-200730060-00005","article-title":"Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase","volume":"30","author":"Edwards","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.athplu.2026.100576_bib75","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00002018-200932080-00004","article-title":"Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects study","volume":"32","author":"Golomb","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.athplu.2026.100576_bib76","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40264-017-0620-4","article-title":"Amyotrophic lateral sclerosis associated with Statin use: a disproportionality analysis of the FDA's adverse event reporting system","volume":"41","author":"Golomb","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.athplu.2026.100576_bib77","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1007\/s10072-022-06131-7","article-title":"Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"43","author":"Hu","year":"2022","journal-title":"Neurol Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib78","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCOUTCOMES.110.936278","article-title":"Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders","volume":"3","author":"Sorensen","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.athplu.2026.100576_bib79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/21678421.2018.1511731","article-title":"Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly","volume":"19","author":"Freedman","year":"2018","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.athplu.2026.100576_bib80","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ana.26600","article-title":"Protective effects of lovastatin in a population-based ALS study and mouse model","volume":"93","author":"Kreple","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib81","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1007\/s00415-024-12665-x","article-title":"Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: a meta-analysis and Mendelian randomisation study","volume":"271","author":"Chalitsios","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13760-023-02393-w","article-title":"Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study","volume":"124","author":"Yan","year":"2024","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.athplu.2026.100576_bib83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jns.2008.06.022","article-title":"Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis","volume":"273","author":"Drory","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jns.2010.10.011","article-title":"Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis","volume":"300","author":"Nefussy","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.athplu.2026.100576_bib85","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/ene.14300","article-title":"Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany","volume":"27","author":"Schumacher","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/17482960802031092","article-title":"Are statin medications safe in patients with ALS?","volume":"9","author":"Zinman","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.athplu.2026.100576_bib87","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/ene.14190","article-title":"Antidiabetics, statins and the risk of amyotrophic lateral sclerosis","volume":"27","author":"Mariosa","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib88","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/aje\/kwac054","article-title":"Statin medications and amyotrophic lateral sclerosis incidence and mortality","volume":"191","author":"Weisskopf","year":"2022","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.athplu.2026.100576_bib89","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.25048","article-title":"Statins accelerate disease progression and shorten survival in SOD1(G93A) mice","volume":"54","author":"Su","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.athplu.2026.100576_bib90","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41419-021-03669-w","article-title":"Simvastatin accelerated motoneurons death in SOD1(G93A) mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles","volume":"12","author":"Bai","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.athplu.2026.100576_bib91","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2474-13-100","article-title":"Selected statins produce rapid spinal motor neuron loss in vitro","volume":"13","author":"Murinson","year":"2012","journal-title":"BMC Muscoskelet Disord"},{"key":"10.1016\/j.athplu.2026.100576_bib92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neulet.2018.04.006","article-title":"Autophagy as a common pathway in amyotrophic lateral sclerosis","volume":"697","author":"Nguyen","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.athplu.2026.100576_bib93","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","article-title":"Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis","volume":"7","author":"Ferraiuolo","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.athplu.2026.100576_bib94","first-page":"RA73","article-title":"Statins and ALS: the possible role of impaired LXR signaling","volume":"16","author":"Beltowski","year":"2010","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.athplu.2026.100576_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1422912","article-title":"The role of statins in amyotrophic lateral sclerosis: protective or not?","volume":"18","author":"Al-Kuraishy","year":"2024","journal-title":"Front Neurosci"},{"key":"10.1016\/j.athplu.2026.100576_bib96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/138945010790031018","article-title":"Coenzyme Q10 in neuromuscular and neurodegenerative disorders","volume":"11","author":"Mancuso","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.athplu.2026.100576_bib97","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1007\/s12035-024-04007-9","article-title":"Discovery and exploration of lipid-modifying drug targets for ALS by Mendelian randomization","volume":"61","author":"Jiang","year":"2024","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.athplu.2026.100576_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3543","article-title":"Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: a drug target Mendelian randomization study","volume":"14","author":"Huang","year":"2024","journal-title":"Brain Behav"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:49:48Z","timestamp":1790264988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089526000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":98,"alternative-id":["S2667089526000313"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2026.100576","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholesterol in amyotrophic lateral sclerosis: a bystander, a biomarker, or a target?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2026.100576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100576"}}